Michel Afargan
Chief Scientific Officer, Head Drug Developments and Radiopharmaceutical Strategies Starget Pharma
Seminars
Wednesday 22nd July 2026
Accelerating Radioligand Discovery: Leveraging In Silico Screening & AI to Overcome Lead-Finding Bottlenecks
2:00 pm
- Exploring what works and what does not in existing AI and in silico platforms for faster target and hit identification
- Comparing approaches across modalities, from small molecules to antibodies, to see what drives pipeline success
- Identifying the real bottlenecks in hit discovery and optimization, so screens yield more actionable leads
